tetano
Editor, Senior Moderator
Hematol Rep
. 2021 Mar 12;13(1):8857.
doi: 10.4081/hr.2021.8857. eCollection 2021 Mar 5.
Heparin-induced thrombocytopenia and COVID-19
Michelangelo Sartori[SUP] 1 [/SUP], Benilde Cosmi[SUP] 1 2 [/SUP]
Affiliations
Abstract
Heparin-induced thrombocytopenia (HIT) has not been included as a possible cause of thrombocytopenia in Coronavirus Disease 2019 (COVID-19) patients. We report a case of HIT in a patient with COVID-19 treated with heparin. A 78-yearold man was admitted to our hospital for acute respiratory failure and acute renal failure due to SARS-CoV-2 infection; in intensive care unit, one 5000IU heparin dose (day 0, platelet count 305000/?L). On day 2, haemoglobin started to decrease and heparin was stopped. On day 10, platelet count was 153000/?L and 5000IU calcium heparin subcutaneously twice daily was started. The platelet further decreased, reaching 49000/?L on day 17, and the patient was investigated for suspected HIT: an IgG specific chemiluminescence test for heparin- PF4 antibodies was positive and a femoral DVT was found at ultrasound. Argatroban was started, platelet count increased without any bleeding and thrombosis complication. Our experience shows that HIT may develop in heparin treated COVID-19 patients and should be included among the possible cause of thrombocytopenia in such patients.
Keywords: COVID-19; Heparin-ind
. 2021 Mar 12;13(1):8857.
doi: 10.4081/hr.2021.8857. eCollection 2021 Mar 5.
Heparin-induced thrombocytopenia and COVID-19
Michelangelo Sartori[SUP] 1 [/SUP], Benilde Cosmi[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33747413
- PMCID: PMC7970398
- DOI: 10.4081/hr.2021.8857
Abstract
Heparin-induced thrombocytopenia (HIT) has not been included as a possible cause of thrombocytopenia in Coronavirus Disease 2019 (COVID-19) patients. We report a case of HIT in a patient with COVID-19 treated with heparin. A 78-yearold man was admitted to our hospital for acute respiratory failure and acute renal failure due to SARS-CoV-2 infection; in intensive care unit, one 5000IU heparin dose (day 0, platelet count 305000/?L). On day 2, haemoglobin started to decrease and heparin was stopped. On day 10, platelet count was 153000/?L and 5000IU calcium heparin subcutaneously twice daily was started. The platelet further decreased, reaching 49000/?L on day 17, and the patient was investigated for suspected HIT: an IgG specific chemiluminescence test for heparin- PF4 antibodies was positive and a femoral DVT was found at ultrasound. Argatroban was started, platelet count increased without any bleeding and thrombosis complication. Our experience shows that HIT may develop in heparin treated COVID-19 patients and should be included among the possible cause of thrombocytopenia in such patients.
Keywords: COVID-19; Heparin-ind